Skip to main content
Equibles
MDGL logo

MDGL · Madrigal Pharmaceuticals, Inc. · Metrics

Track MDGL — free

Use MDGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MDGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$474.12 +6.58 (+1.41%)
Russell 1000 member Rebalance outlook locked
Market Cap
$10.80B
Shares
23.10M
Volume · Oct 21 18.64K Avg daily vol (3M) 294.81K

MDGL metrics

80 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$467.54
Market cap
$10.80B

Price action

20 metrics
Price change (1W)
+3.4%
Price change (30D)
-10.4%
Price change (3M)
-14.5%
Price change (6M)
-11.4%
Price change (YTD)
-19.7%
Price change (1Y)
+6.3%
Trailing year
Price change (5Y)
+489.2%
52-week high
$602.83
52-week low
$412.35
Change from 52-week high
-22.4%
Change from 52-week low
+13.4%
Annualized volatility
43.7%
Annualized volatility (3M)
38.9%
Beta
0.4
RSI (14D)
39.1
Price vs SMA 50
-8.7%
Price vs SMA 200
-7.2%
Avg volume (3M)
294,808
Relative volume
1.4
Average dollar volume
$149.82M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
23.10M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
8.5×
reciprocal yield 11.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
8.4×
reciprocal yield 11.9%
P / book
20.6
reciprocal yield 4.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
13.6×
reciprocal yield 7.4%
EV / revenue historical average (5Y)
13.6×
reciprocal yield 7.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
—
Operating margin
-25.1%
Trailing 12 months
Net margin
-25.3%
Gross profit (TTM)
$306.64M
Operating profit (TTM)
−$322.62M
Net income (TTM)
−$325.10M
Trailing 12 months
Diluted EPS (TTM)
$-11.28
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$44.45
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-11.19
EBITDA per diluted share (TTM)
$-11.14
Net income per diluted share (TTM)
$-11.28
Operating cash flow per diluted share (TTM)
$-6.80
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$17.01
Stock compensation per diluted share (TTM)
$4.20
Book value per share
$26.39

Growth

11 metrics
Revenue growth YoY
+71.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.28B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-62.1%
Return on assets
-26.1%
Debt / equity
0.7
Current ratio
3.2
EBITDA (TTM)
−$321.10M
Free cash flow (TTM)
—
Quick ratio
2.9
Interest coverage
-10.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$48.07M
Latest balance sheet
Cash & equivalents
$292.73M
Total assets
$1.24B
Total debt
$340.79M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$197.72M
Capital expenditures (TTM)
$8.57M
R&D (TTM)
$490.14M
SG&A (TTM)
$1.01B
Stock compensation (TTM)
$121.43M
R&D / revenue
38.2%
Stock compensation / revenue
9.5%

Ownership (13F)

9 metrics
13F filers
419
13F filer change QoQ
+33
Institutional ownership
107.1%
Conviction holders (share of 13F filers)
2.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.3%
Holder tenure
14.6
Price vs estimated holder cost
+62.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.6%

Short interest

3 metrics
Short interest
10.4%
Latest settlement · 9.8 days to cover
Days to cover
9.8d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$6.58M
Insider-sentiment score
49 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1157601 CUSIP 558868105 13F (30d) 48 filings 48 filers Visit website Investor relations